High-Sensitivity Cardiac Troponin I Assay Validated
By LabMedica International staff writers Posted on 20 Sep 2018 |
Image: High-sensitivity troponin I assays (TnIH) for the Atellica IM and ADVIA Centaur XP/XPT in vitro diagnostic analyzers to aid in the early diagnosis of myocardial infarctions (Photo courtesy of Siemens Healthineers).
Myocardial infarction (MI), commonly known as a heart attack occurs when blood flow decreases or stops to a part of the heart, causing damage to the heart muscle. The most common symptom is chest pain or discomfort which may travel into the shoulder, arm, back, neck, or jaw.
The diagnosis of myocardial infarction requires two out of three components, history, electrocardiogram (ECG), and levels of certain enzymes. When damage to the heart occurs, levels of cardiac markers rise over time, which is why blood tests for them are taken over a 24-hour period.
Scientists at the University Hospital Basel (Basel, Switzerland) and their international colleagues enrolled 1,755 patients presenting to the emergency department with symptoms suggestive of acute myocardial infarction (AMI). Final diagnoses were centrally adjudicated by two independent cardiologists including all clinical information twice.
The team used serial Troponin T-high sensitive assay for primary analysis; secondly, they used using High Sensitive Troponin-I for secondary analysis measurements. In addition they clinically applied high sensitivity cardiac troponin (hs-cTnI), which was measured at presentation, one hour and two hours.
AMI was the final diagnosis in 318 of 1,755 (18%) patients using the Roche-hs-cTnT-Elecsys for adjudication. The area under the curve (AUC) at presentation for Siemens-hs-cTnI-Centaur was 0.94 and comparable with 0.95 for Roche-hs-cTnT-Elecsys and 0.93 for Abbott-hs-cTnI-Architect. Applying the derived Siemens-hs-cTnI-Centaur 0/1-h algorithm to the validation cohort, 46% of patients were ruled out (sensitivity, 99.1%, and 18% of patients were ruled in, specificity, 94.1%. The Siemens-hs-cTnI-Centaur 0/2-h algorithm ruled out 55% of patients (sensitivity, 100%), and ruled in 18% of patients (specificity, 96.0%). Findings were confirmed in the secondary analyses using serial measurements of Abbott-hs-cTnI-Architect for adjudication.
The authors concluded that diagnostic accuracy and clinical utility of the novel Siemens-hs-cTnI-Centaur assay are high and comparable with the established hs-cTn assays. The study was published in August 2018 in the journal Clinical Chemistry.
Related Links:
University Hospital Basel
The diagnosis of myocardial infarction requires two out of three components, history, electrocardiogram (ECG), and levels of certain enzymes. When damage to the heart occurs, levels of cardiac markers rise over time, which is why blood tests for them are taken over a 24-hour period.
Scientists at the University Hospital Basel (Basel, Switzerland) and their international colleagues enrolled 1,755 patients presenting to the emergency department with symptoms suggestive of acute myocardial infarction (AMI). Final diagnoses were centrally adjudicated by two independent cardiologists including all clinical information twice.
The team used serial Troponin T-high sensitive assay for primary analysis; secondly, they used using High Sensitive Troponin-I for secondary analysis measurements. In addition they clinically applied high sensitivity cardiac troponin (hs-cTnI), which was measured at presentation, one hour and two hours.
AMI was the final diagnosis in 318 of 1,755 (18%) patients using the Roche-hs-cTnT-Elecsys for adjudication. The area under the curve (AUC) at presentation for Siemens-hs-cTnI-Centaur was 0.94 and comparable with 0.95 for Roche-hs-cTnT-Elecsys and 0.93 for Abbott-hs-cTnI-Architect. Applying the derived Siemens-hs-cTnI-Centaur 0/1-h algorithm to the validation cohort, 46% of patients were ruled out (sensitivity, 99.1%, and 18% of patients were ruled in, specificity, 94.1%. The Siemens-hs-cTnI-Centaur 0/2-h algorithm ruled out 55% of patients (sensitivity, 100%), and ruled in 18% of patients (specificity, 96.0%). Findings were confirmed in the secondary analyses using serial measurements of Abbott-hs-cTnI-Architect for adjudication.
The authors concluded that diagnostic accuracy and clinical utility of the novel Siemens-hs-cTnI-Centaur assay are high and comparable with the established hs-cTn assays. The study was published in August 2018 in the journal Clinical Chemistry.
Related Links:
University Hospital Basel
Latest Clinical Chem. News
- 3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models
- POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection
- Highly Reliable Cell-Based Assay Enables Accurate Diagnosis of Endocrine Diseases
- New Blood Testing Method Detects Potent Opioids in Under Three Minutes
- Wireless Hepatitis B Test Kit Completes Screening and Data Collection in One Step
- Pain-Free, Low-Cost, Sensitive, Radiation-Free Device Detects Breast Cancer in Urine
- Spit Test Detects Breast Cancer in Five Seconds
- Electrochemical Sensors with Next-Generation Coating Advances Precision Diagnostics at POC
- First-Of-Its-Kind Handheld Device Accurately Detects Fentanyl in Urine within Seconds
- New Fluorescent Sensor Array Lights up Alzheimer’s-Related Proteins for Earlier Detection
- Automated Mass Spectrometry-Based Clinical Analyzer Could Transform Lab Testing
- Highly Sensitive pH Sensor to Aid Detection of Cancers and Vector-Borne Viruses
- Non-Invasive Sensor Monitors Changes in Saliva Compositions to Rapidly Diagnose Diabetes
- Breakthrough Immunoassays to Aid in Risk Assessment of Preeclampsia
- Urine Test for Monitoring Changes in Kidney Health Markers Can Predict New-Onset Heart Failure
- AACC Releases Comprehensive Diabetes Testing Guidelines